A rotator cuff tear is a common cause of shoulder pain and disability. Credit: create jobs 51 / Shutterstock.com.

Inovedis has received the US Food and Drug Administration (FDA) approval for its new implant system, SINEFIX, for rotator cuff tears repair.

Using a simplified surgical technique, the implant system helps refix the rotator cuff tendon to the bone.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In contrast to traditional surgery, the new technique not only provides effective mechanical reinforcement of the fixed tendon but also stimulates the intrinsic healing capability of the patient.

The staple implant has been designed to create a flat and even contact between tendon and bone.

The device ensures uniform shear stress and prevents punctual pressure peaks while maintaining blood circulation to support the healing process.

It will be inserted using a two-step technique: the base plate is placed in position and the fixation points are driven into the bone using a hammer and the company’s specialised SINEFIX instruments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This technique helps reduce surgery time and lower the risk of complications due to surgical errors.

Inovedis founder and CEO Lukas Flöss said: “With FDA clearance we will now initiate a first mover application to generate real-world experience in the US to evaluate the potential of the technology.

“We are looking forward to the launch of SINEFIX at the upcoming American Orthopaedic Society for Sports Medicine annual meeting on 13-16 July in Washington DC, followed by enrolling clinical sites into our limited market release to begin gathering experience around SINEFIX.”

Established in 2019, Inovedis concluded a financing round led by High-Tech Gründerfonds after initial funding from the Startup BW PreSeed.